Epidarex Venture Partner Terri Burke will be a featured speaker at Cooley x JLABS @ TMC : Medtech Startup Fundamentals
In All, EpidarexPlease click here to view the event’s agenda.
05
Sep
Epidarex
Epidarex Capital – Catalyzing innovation in health science and technology
03
Sep
Apellis Dosed First Patient in Phase 3 Study of APL-2 for Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria
In All, PortfolioCRESTWOOD, Ky. and WALTHAM, Mass., – Apellis Pharmaceuticals Inc., (Nasdaq:APLS) announced today the dosing of the first patient in the Phase 3 clinical study PRINCE (APL2-308), evaluating the efficacy and safety of APL-2 for treatment-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH). PRINCE is the second Phase…
29
Aug
LifeArc Seed Fund Makes £1.5million Investment in Caldan Therapeutics to Develop Novel Treatments for Metabolic Diseases
In All, PortfolioLifeArc, a UK-based medical research charity, announced today it is investing £1.5million into Caldan Therapeutics Limited, a company developing novel therapeutics for the treatment of metabolic diseases based on original work. Focusing on activators of free fatty acid receptors (GPR120) implicated in the development of…
24
Jul
Epidarex Co-founder and Managing Partner Kyp Sirinakis Joins TEDCO’s New Task Force for Women Entrepreneurs
In All, EpidarexEpidarex co-founder and managing partner Kyp Sirinakis has joined TEDCO’s new Task Force for Women Entrepreneurs. The task force is dedicated to the recruitment, funding, and operational support of women-owned and-led startups in Maryland. Click here to view the full press release.
22
Jul
Apellis Pharmaceuticals Expands Leadership Team, Appoints Lucia Celona as Chief People Officer
In All, PortfolioCRESTWOOD, Ky. and WALTHAM, Mass., – Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced today the appointment of Lucia Celona as Chief People Officer. Prior to…
18
Jul
Apellis Pharmaceuticals Will Commence APL-9 Program to Control the Complement System in Host Responses to AAV Vector Administration for Gene Therapies
In All, PortfolioCRESTWOOD, Ky. and WALTHAM, Mass., – Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the control of the complement system, today announced its plans to develop APL-9 for the prevention of complement immune…
27
Jun
Apellis Pharmaceuticals Completes Enrollment of Phase 3 APL-2 (pegcetacoplan) Head-to-Head Study in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab
In All, PortfolioTop-line Data Anticipated in December 2019 CRESTWOOD, Ky. and WALTHAM Mass., June 27, 2019 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced the…
10
Apr
NodThera Highlights Significant Progress with Advancement of Lead Development Candidate and Key Additions to Board
In All, PortfolioCompany advances NT-0167 as first development candidate from a broad platform of NLRP3 inflammasome inhibitors Appoints Don Nicholson as Board Chairman and Kevin Lee as Independent Director Cambridge, UK, Boston and Seattle – April 10th, 2019 – NodThera, a biotechnology company developing a new class…
09
Apr
IGEM Therapeutics Appoints Dr David Chiswell as a Non-Executive Chairman
In All, PortfolioCambridge Antibody Technology co-founder and CEO, Dr Chiswell brings 30 years of biotechnology experience to IGEM’s Board London, 9 April 2019 – IGEM Therapeutics (IGEM), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, announces that Dr David Chiswell will be joining…
25
Mar
Enterprise Therapeutics Strengthens Leadership Team, Appoints Amit D. Munshi as Non-Executive Chairman
In All, PortfolioAppointment brings significant commercial pharma experience as Enterprise Therapeutics’ two lead respiratory programmes are progressed towards the clinic Brighton, UK: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory…